CHMP supports label extension of Leo Pharma's atopic eczema treatment

Adtralza, which is already on the eczema treatment market for adults, has now been recommended for treating patients with the skin disease who are as young as 12.

Photo: Leo Pharma / PR

Danish drugmaker Leo Pharma’s atopic eczema treatment Adtralza (tralokinumab) should not be exclusive to adults, said the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) during its September meeting.

The committee responsible for advising the EU Commission on drug matters therefore recommends that adolescents as young 12 gain access to the treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs